bosentandaratumumabazacitidineibrutinibnintedanibrare diseasesRDORPHANETnational health authorities
… (14.8%), nintedanib (11.3%), ibrutinib (10%), azacitidine, and bosentan (7.8%). OD distribution by ATC group was dominated by L (n=19),…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 322 of 2459erenumabgalcanezumabfremanezumabmigraine
…as 85.4% for galcanezumab, 81.3% for fremanezumab and 84.2% for erenumab; at 4 years it was 69.2%, 73.5% and 63.9% respectively. Among 6…
Cladribinetertiary hospitalrelapsing–remitting multiple sclerosisRRMSDMT
…Background and Importance Cladribine is an immunosuppressive drug used in relapsing–remitting multip…
97.2%
faricimabafliberceptranibizumabdiabetic macular oedemaretinal diseasesretinal vein occlusionVabysmoAMDDME
…r centre’s experience.Aim and Objectives To evaluate the use of faricimab and its economic impact from the hospital pharmacy perspective.…
gentamicinhospital infectionspenicillin
…eatments, more than half were inappropriate: the first doses of gentamicin were too low (51%), while in a smaller portion (15%) the first …
adalimumabmoderate-to-severe psoriasisEQ-5DPsoriasisbiologicsdermatologybiologic therapy
…%) had a PSSD > 20 and were referred. Among them, 61.4% were on adalimumab, and 54.5% were on first-line therapy. The median PASI score at…
sepsisantibiotic therapytertiary hospitalantimicrobial therapy
…ented in Madrid to standardise early detection and treatment of sepsis.Aim and Objectives Primary objective: to analyse the percentage…
pembrolizumabatezolizumabnivolumabimmunotherapysolid tumoursnon-small-cell lung cancersmall-cell lung cancermetastatic diseasesix hospitals
…ucted, including all patients who received at least one dose of pembrolizumab, nivolumab, or atezolizumab as first-line treatment for metasta…
piperacillin-tazobactammeropenemPiperDose-UCIcritically ill patientsantimicrobial stewardship programspiperacillinMeroDose-UCI
… MAE = 1.15 ± 1.80 mg/L, MRE = 11.5 ± 8.6%.Population model for piperacillin-tazobactam: R2 = 0.86, MAE = 9.31 ± 19.33 mg/L, MRE = 38.4 ± 19.5%; after …
palivizumabnirsevimabRSV
…l budget savings and broader prophylaxis coverage compared with palivizumab. Its single-dose schedule demonstrates greater economic efficie…
pneumoniaCLARclarithromycinMerckpulmonology departmentICU
…ay, n=63 cases; corrected to kidney function, n=2 cases) due to pneumonia. Blood sample collection was performed on day 3 of the CLAR adm…
recurrent cholangitiscolistinenystatintobramycinthird-degree hospitalcholangitisONA
…s conducted in a third-degree hospital, including patients with recurrent cholangitis who received ONA treatment between November 2018 and August 202…